🇮🇳 Biocon Ltd

Press Release 16-11-2026 08:36:08 IST

Overview: U.S. FDA has approved Pebrilzo (pertuzumab-qcay) injection, a biosimilar to Perjeta for HER2-positive breast cancer, with a planned U.S. launch in Q3 2028.

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest